Volatility over trade and foreigh currencies: He likes the opportunities that volatility brings. Lack of it breeds complacency. Valuations in tech are getting pretty high and he suspects there will be a rotation out of tech. He's moving into energy where there are bargains. (He has a 12-24-month outlook.) This has been a momentum market, but focus on the future, not tomorrow morning. Oil is down today, but the oil chart over the past year is bullish overall. In two or three years there could be c.2007 discussions of there being not enough oil. In Canada, these stocks have come off a lot since the TransMountain court ruling, but the new Enbridge line 3 should be operating by end-2019. In addition, Keystone or TransMountain will go through (he's confident that TM will under Trudeau).

He recently bought this. This was an undervalued company and heavily levered. They recently merged with Raging River, making it worth investing in now. It was beaten up along with other oil stocks, but he likes the story of this stock
now.

The U.S. market is outperforming Canada, so he prefers financials there than here. MS had a recent pullback, but feels it will do well going forward. The U.S. financials will move in a pack. You should get a decent return in MS in the next 12 months.

More of a wireless than a telco company. Growth has really slowed down in this sector, yet cell phones remain an essential business. He likes Verizon and it's a little pricey now, but good long-term. Pays a nice dividend.

Avoid it. Franchisees fighting with the company is not a good sign. Horton's has been a great brand, but after the QSR takeover, QSR has cut corners too much and franchisees are now pushing back. Also, the U.S. expansion didn't work.

A leader in generic pharmaceuticals. It's sold off the past few years and he hasn't look at it recently. Hold on. It's bottoming. Look at its fundamentals. This is the right sector, but do your homework on it.

A cheap stock. This is a great leveraged play on the price of zinc. Buying this depends on where you think the price of zinc will go.

Pretty disappointing after last fall's announcement to have an Asian pharma company come in and get the rights to CaPre, their phase-3 development drug to treat cholesterol. It looked promising, but ACST hold off on the deal after a few new parties showed interest in CaPre. The market is disappointed the deal didn't happen and punished this stock. He believes this company could be worth $1 billion in two three years. The promise is still there, but you have to wait. Watch the phase 3 drug trials into next year.